Study of Karenitecin (BNP1350) in Patients With Brain Tumors

Inclusion Criteria

• •Confirmed diagnosis of a newly diagnosed glioblastoma multiforme or recurrent/progressive glioblastoma multiforme, anaplastic astrocytoma, or anaplastic oligodendroglioma.
• •Evidence of measurable recurrent or residual primary CNS neoplasm.
• •An interval of at least 3 weeks between prior surgical resection or 6 weeks between prior radiotherapy or chemotherapy, and enrollment on this protocol unless there is unequivocal evidence of tumor progression after surgery, radiotherapy, or chemotherapy.
• •Hematocrit \> 29%, ANC \> 1,500, platelets \> 125,000
• •Serum creatinine \< 1.5 mg/dl, BUN \< 25 mg/dl, serum SGOT and bilirubin \< 1.5 times upper limit of normal
• •Negative pregnancy test for female patients